ABArtun Bulbul

Artun Bulbul

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Artun Bulbul has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Asli Gulce Bartan

    Molecular Biology and Genetics Department Bilkent University Ankara Turkey

    2 shared publications
  • Basak Kayaoglu

    Department of Biological Sciences Middle East Technical University Ankara Turkey

    2 shared publications
  • Berfu Saraydar

    Molecular Biology and Genetics Department Bilkent University Ankara Turkey

    2 shared publications
  • Bilgehan Ibibik

    Molecular Biology and Genetics Department Bilkent University Ankara Turkey

    2 shared publications
  • Bilgi Gungor

    Molecular Biology and Genetics Department Bilkent University Ankara Turkey

    2 shared publications
  • Fahriye Sarac

    Pendik Veterinary Research and Control Institute Istanbul Turkey

    2 shared publications

Latest Publications

  • Open Access

    Development and preclinical evaluation of virus‐like particle vaccine against COVID‐19 infection

    by Ismail Cem Yilmaz, Emre Mert Ipekoglu, Artun Bulbul, Nilsu Turay, Muzaffer Yildirim, Irem Evcili, Naz Surucu Yilmaz, Nese Guvencli, Yagmur Aydin, Bilgi Gungor, et al.

    Background: Vaccines that incorporate multiple SARS‐CoV‐2 antigens can further broaden the breadth of virus‐specific cellular and humoral immunity. This study describes the development and immunogenicity of SARS‐CoV‐2 VLP vaccine that incorporates the four structural proteins of SARS‐CoV‐2.Methods: VLPs were generated in transiently transfected HEK293 cells, purified by multimodal chromatography, and characterized by tunable‐resistive pulse sensing, AFM, SEM, and TEM. Immunoblotting studies verified the protein identities of VLPs. Cellular and humoral immune responses of immunized animals demonstrated the immune potency of the formulated VLP vaccine.Results: Transiently transfected HEK293 cells reproducibly generated vesicular VLPs that were similar in size to and expressing all four structural proteins of SARS‐CoV‐2. Alum adsorbed, K3‐CpG ODN‐adjuvanted VLPs elicited high titer anti‐S, anti‐RBD, anti‐N IgG, triggered multifunctional Th1‐biased T‐cell responses, reduced virus load, and prevented lung pathology upon live virus challenge in vaccinated animals.Conclusion: These data suggest that VLPs expressing all four structural protein antigens of SARS‐CoV‐2 are immunogenic and can protect animals from developing COVID‐19 infection following vaccination.


  • Open Access

    Development and Preclinical Evaluation of Virus Like Particle Vaccine Against COVID-19 Infection

    by Ismail Yilmaz C, Emre Ipekoglu, Artun Bulbul, Nilsu Turay, Muzaffer Yildirim, Irem Evcili, Naz Yilmaz, Yagmur Aydin, Nese Guvencli, Bilgi Gungor, et al.

    Background Vaccines that incorporate multiple SARS-CoV-2 antigens can further broaden the breadth of virus-specific cellular and humoral immunity. This study describes the development and immunogenicity of SARS-CoV-2 VLP vaccine that incorporates the 4 structural proteins of SARS-CoV-2. Methods VLPs were generated in transiently transfected HEK293 cells, purified by multimodal chromatography and characterized by tunable resistive pulse sensing, AFM, SEM, and TEM. Immunoblotting studies verified the protein identities of VLPs. Cellular and humoral immune responses of immunized animals demonstrated the immune potency of the formulated VLP vaccine. Results Transiently transfected HEK293 cells reproducibly generated vesicular VLPs that were similar in size to and expressing all four structural proteins of SARS-CoV-2. Alum adsorbed, K3-CpG ODN adjuvanted VLPs elicited high titer anti-S, anti-RBD, anti-N IgG, triggered multifunctional Th1 biased T cell responses, reduced virus load and prevented lung pathology upon live virus challenge in vaccinated animals. Conclusion These data suggest that VLPs expressing all four structural protein antigens of SARS-CoV-2 are immunogenic and can protect animals from developing COVID-19 infection following vaccination.